|
|
|
13.04.26 - 18:03
|
IBA – ACQUISITION OF OWN SHARES (GlobeNewswire EN)
|
|
|
Louvain-la-Neuve, Belgium, April 13th, 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on February 2nd, 2026....
|
|
|
|
|
11.04.26 - 05:01
|
US Nuclear Fusion Startup To Build Radioactive Batteries For Use In Space (ZeroHedge)
|
|
|
US Nuclear Fusion Startup To Build Radioactive Batteries For Use In Space
Authored by Ameya Paleja via Interesting Engineering,
Avalanche Energy, a fusion energy startup, has won a $5.2 million contract to build radioactive batteries that can power a laptop-class system for months. The contract is part of the Defense Advanced Research Projects Agency's Rads to Watts Program, which aims to build next-generation, compact, resilient nuclear batteries with higher densities.
An early prototype of Avalanche Energy's radiovoltaic converter for the DARPA Rads to Watts program is exposed to high-energy ion-beam irradiation.Avalanche Fusion
Radioactive batteries aren't an entirely new concept. They have been around for years and have made their way even to Mars on NASA's Perseverance and Curiosity rovers. Another type of radioactive battery is used in medical implant devices and sensors, but all these devices face the same issue: low energy density.
Lithium-ion batteries, which are used everywhe...
|
|
|
|
|
|
|
|
|
|
|
07.04.26 - 18:03
|
IBA – ACQUISITION OF OWN SHARES (GlobeNewswire EN)
|
|
|
Louvain-la-Neuve, Belgium, April 7th, 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on February 2nd, 2026....
|
|
|
|
|
02.04.26 - 19:03
|
Celyad Oncology Reports Full Year 2025 Financial Results and Business Highlights (Business Wire)
|
|
|
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News:
Celyad Oncology (Euronext: CYAD) (the “Company”), today announces its financial results for the fiscal year ended December 31, 2025, and provides a business update.
2025 business and operational highlights
The Company remains focused on partnering its intellectual property and has progressed in the discussions with potential partners for selected out-licensing of its technologies;
The Company discontinued its R&D activities and sold its research facility for €3 million.
Full year 2025 financial review
As of December 31, 2025, the Company's Treasury position amounts to €1.7 million.
The Company projects that its existing cash and cash equivalents should be sufficient to fund operating expenses and capital expenditure requirements into third quarter 2026. Hence, its existing cash and cash equivalents will not be sufficient to fund its estimated operating and capital expenditures over at least the next 12 months from the date that the fi...
|
|
|
|
|
|
|
|
|
|
|
30.03.26 - 19:33
|
IBA – ACQUISITION OF OWN SHARES (GlobeNewswire EN)
|
|
|
Louvain-la-Neuve, Belgium, March 30th, 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on February 2nd, 2026....
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
